论文部分内容阅读
目的探讨新诊断T2DM患者与健康人群血清microRNA(miRNA)表达谱的差异表达。分析利拉鲁肽治疗前后血清miRNA-19a表达水平的变化,并分析其与胰岛β细胞功能变化的相关性。方法采用μParaflo~(TM)miRNA微流体芯片技术检测并筛选出血清中表达丰度有变化的miR-19a,分别测定使用利拉鲁肽治疗前后HbA_1C、血清miR-19a表达和胰岛功能水平。结果芯片检测发现,差异表达最明显的miRNA有12个,选取miR-19a进行PCR验证。利拉鲁肽治疗12周后,血清中miR-19a表达量和HbA_1c分别为(0.04±0.03)%、(6.13±0.57)%,较治疗前降低;胰岛素0~30 min曲线下面积(AUC_(Ins 0~30))与血糖AUC(AUC_(g 0~30))比值(INSR30),AUC_(Ins 0~120)/AUC_(g 0~120)比值(INSR120)及Matsuda胰岛素、敏感指数分别为(1.93±0.63)、(3.94±2.27)及(7.86±3.81),较治疗前增加(P<0.05)。结论利拉鲁肽治疗新诊断T2DM,胰岛β细胞功能的改善可能与血清中miR-19a表达下调有关。
Objective To explore the differential expression of serum microRNA (miRNA) expression profiles in newly diagnosed T2DM patients and healthy subjects. The changes of serum miRNA-19a expression before and after liraglutide treatment were analyzed, and their correlations with the changes of pancreatic β-cell function were analyzed. Methods μParaflo TM miRNA micro-fluid microarray was used to detect and screen the expression of miR-19a in serum. The levels of HbA 1 C, serum miR-19a and islet function were measured before and after treatment with liraglutide. Results The results of microarray detection showed that there were 12 miRNAs with the most differential expression, and miR-19a was selected for PCR validation. After 12 weeks of liraglutide treatment, the expression of miR-19a and HbA_1c in serum were (0.04 ± 0.03)% and (6.13 ± 0.57)%, respectively, which were lower than those before treatment. The area under the curve of insulin 0-30min (AUC_ Ins 0-30 and INSR30, AUC Ins 0-120 / AUC g 0-120, INSR120 and Matsuda insulin, respectively, and the sensitivity indexes were (1.93 ± 0.63), (3.94 ± 2.27) and (7.86 ± 3.81) respectively, which were significantly higher than those before treatment (P <0.05). Conclusion Liraglutide treatment of newly diagnosed T2DM, pancreatic β-cell function may be related to the reduction of serum miR-19a expression.